Analysts See $-0.57 EPS for Ra Pharmaceuticals, Inc. (RARX); Tandy Leather Factory (TLF)’s Sentiment Is 1.43

April 30, 2018 - By Adrian Erickson

Tandy Leather Factory, Inc. (NASDAQ:TLF) Logo

Tandy Leather Factory Inc (TLF) investors sentiment decreased to 1.43 in Q4 2017. It’s down -0.07, from 1.5 in 2017Q3. The ratio has dropped, as 10 funds increased or started new equity positions, while 7 sold and reduced their holdings in Tandy Leather Factory Inc. The funds in our database now own: 4.89 million shares, up from 4.64 million shares in 2017Q3. Also, the number of funds holding Tandy Leather Factory Inc in top ten equity positions was flat from 1 to 1 for the same number . Sold All: 4 Reduced: 3 Increased: 6 New Position: 4.

Analysts expect Ra Pharmaceuticals, Inc. (NASDAQ:RARX) to report $-0.57 EPS on May, 10.They anticipate $0.07 EPS change or 14.00% from last quarter’s $-0.5 EPS. After having $-0.67 EPS previously, Ra Pharmaceuticals, Inc.’s analysts see -14.93% EPS growth. The stock decreased 3.43% or $0.21 during the last trading session, reaching $5.91. About 30,783 shares traded. Ra Pharmaceuticals, Inc. (NASDAQ:RARX) has declined 74.40% since April 30, 2017 and is downtrending. It has underperformed by 85.95% the S&P500.

The stock decreased 2.27% or $0.168 during the last trading session, reaching $7.232. About 712 shares traded. Tandy Leather Factory, Inc. (TLF) has declined 2.03% since April 30, 2017 and is downtrending. It has underperformed by 13.58% the S&P500.

Since January 1, 0001, it had 1 insider buy, and 0 selling transactions for $1,855 activity.

Tandy Leather Factory, Inc. operates as a retailer and wholesale distributor of a range of leather and related products. The company has market cap of $66.64 million. It operates through three divisions: Wholesale Leathercraft, Retail Leathercraft, and International Leathercraft. It has a 15.07 P/E ratio. The firm offers leather, leatherworking tools, buckles and adornments for belts, leather dyes and finishes, and saddle and tack hardware.

Bandera Partners Llc holds 18.25% of its portfolio in Tandy Leather Factory, Inc. for 2.86 million shares. Beddow Capital Management Inc owns 560,218 shares or 1.76% of their US portfolio. Moreover, Zpr Investment Management has 0.22% invested in the company for 19,391 shares. The California-based Quantum Capital Management has invested 0.12% in the stock. Bridgeway Capital Management Inc, a Texas-based fund reported 106,600 shares.

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company has market cap of $190.81 million. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. It currently has negative earnings. The Company’s lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria , as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP).

Among 3 analysts covering Ra Pharmaceuticals (NASDAQ:RARX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ra Pharmaceuticals had 5 analyst reports since August 24, 2017 according to SRatingsIntel. As per Tuesday, October 24, the company rating was maintained by RBC Capital Markets. Jefferies maintained Ra Pharmaceuticals, Inc. (NASDAQ:RARX) rating on Tuesday, September 26. Jefferies has “Buy” rating and $25.0 target. Credit Suisse maintained the shares of RARX in report on Friday, November 10 with “Outperform” rating. Jefferies maintained the stock with “Buy” rating in Thursday, August 24 report.

Tandy Leather Factory, Inc. (NASDAQ:TLF) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Posts